Identification of factors associated with the efficacy of atomoxetine in adult attention‐deficit/hyperactivity disorder

AIM: Atomoxetine (ATX) is a non‐central stimulant and a standard treatment for adult attention‐deficit/hyperactivity disorder (ADHD). The long‐term efficacy of Atomoxetine is about 40% at 6 months. The variability in efficacy between individuals is thought to be related to patient‐specific factors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Tsutomu, Kurihara, Tatsuya, Koya, Hiroaki, Nakano, Yukako, Sugisawa, Satoru, Sambe, Takehiko, Kishimoto, Keiko, Kogo, Mari, Ota, Haruhisa, Iwanami, Akira, Uchida, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515700/
https://www.ncbi.nlm.nih.gov/pubmed/35485452
http://dx.doi.org/10.1002/npr2.12253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9515700/
https://www.ncbi.nlm.nih.gov/pubmed/35485452
http://dx.doi.org/10.1002/npr2.12253

Ejemplares similares